Allarity Therapeutics (ALLR) News Today → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free ALLR Stock Alerts $1.54 +0.12 (+8.44%) (As of 01:22 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAllarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)finanznachrichten.de - April 17 at 1:58 PMAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)finance.yahoo.com - April 17 at 1:58 PMAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)globenewswire.com - April 17 at 9:10 AMWhy Is Allarity Therapeutics (ALLR) Stock Up 41% Today?investorplace.com - April 12 at 8:18 AMmarketbeat.com - April 9 at 6:00 AMAllarity Therapeutics, Inc.: Allarity Therapeutics Announces 1-for-20 Reverse Stock Splitfinanznachrichten.de - April 4 at 2:45 PMAllarity Therapeutics to implement 1-for-20 reverse stock splitmsn.com - April 4 at 9:45 AMAllarity Therapeutics Announces 1-for-20 Reverse Stock Splitglobenewswire.com - April 4 at 9:15 AMAllarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancerglobenewswire.com - March 27 at 8:30 AMAllarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)globenewswire.com - March 25 at 7:30 AMAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Updatefinanznachrichten.de - March 8 at 11:01 AMAllarity Therapeutics: Q4 Earnings Insightsbenzinga.com - March 8 at 11:01 AMAllarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Updateglobenewswire.com - March 8 at 7:15 AMAllarity Therapeutics to Present at Biomarkers 2024globenewswire.com - February 28 at 6:00 AMAllarity Therapeutics Stock (NASDAQ:ALLR), Short Interest Reportbenzinga.com - February 23 at 7:36 AMAllarity Therapeutics Stock (NASDAQ:ALLR) Dividends: History, Yield and Datesbenzinga.com - February 23 at 7:36 AMBoston biotech loses Novartis drug license agreement for nonpaymentbizjournals.com - February 2 at 3:30 PMAllarity Therapeutics’ Licensing Agreement with Novartis Terminatedmsn.com - February 2 at 3:30 PMAllarity Therapeutics CEO James Cullem Steps Downmarkets.businessinsider.com - December 12 at 9:10 AMAllarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisorfinance.yahoo.com - December 12 at 9:10 AMALLR: Stenoparib Clinical Updatefinance.yahoo.com - December 7 at 10:12 AMAllarity stock soars 60% premarket on ovarian cancer therapy resultsseekingalpha.com - December 6 at 12:46 AMWhy Is Allarity Therapeutics (ALLR) Stock Up 42% Today?investorplace.com - December 5 at 11:01 AMAllarity's Early Phase 2 Stenoparib Data Suggests Encouraging Results In Advanced Ovarian Cancermarkets.businessinsider.com - December 5 at 9:44 AMAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnosticfinance.yahoo.com - December 5 at 9:44 AMAllarity Therapeutics Inc ALLRmorningstar.com - November 10 at 4:02 PMAllarity Therapeutics files for $50M mixed shelfmsn.com - November 2 at 7:21 PMAllarity Therapeutics to Present at Biomarkers Europe 2023finance.yahoo.com - October 2 at 11:02 AMAllarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technologyfinance.yahoo.com - September 14 at 10:26 AMThinking about buying stock in Allarity Therapeutics, Better Home & Finance Holding, Top KingWin, Axcella Health, or Metatron Apps?benzinga.com - August 31 at 5:45 PMWhat's Going On With Allarity Therapeutics Stock?benzinga.com - August 31 at 5:45 PMPre-market Movers: ICCT, NCNC, ALLR, LYRA, MYNZ…markets.businessinsider.com - August 31 at 9:07 AMAllarity's DRP Companion Diagnostic For Dovitinib Earns Peer-Reviewed Spotlight, Stock Jumpsnasdaq.com - August 31 at 4:06 AMPLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinibfinance.yahoo.com - August 30 at 6:05 PMWhy is Allarity Therapeutics Stock Trading Higher Today?msn.com - July 31 at 3:52 PMAllarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnosticsfinance.yahoo.com - July 31 at 10:51 AMALLR: IXEMPRA Clinical Updatefinance.yahoo.com - July 12 at 1:43 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLRmarkets.businessinsider.com - July 7 at 1:47 PMAllarity Therapeutics falls after pricing public offering to raise $11Mseekingalpha.com - July 7 at 8:47 AMWhy Allarity Therapeutics Stock Is Tanking Todaymsn.com - July 6 at 12:43 PMAllarity Therapeutics Shares Slide Premarket After Stock Offering >ALLRmarketwatch.com - July 6 at 7:43 AMAllarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offeringfinance.yahoo.com - July 6 at 7:43 AMAllarity Says Initial Data Show Improved Clinical Benefit In Breast Cancer Patients Selected Via Companion Diagnosticmsn.com - July 5 at 5:27 PMWhy Allarity Therapeutics Stock Is Ripping Higher Wednesdaymsn.com - July 5 at 5:27 PMWhy Is Allarity Therapeutics (ALLR) Stock Up 30% Today?investorplace.com - July 5 at 3:04 PMInitial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patientsfinance.yahoo.com - July 5 at 12:27 PMmarketbeat.com - July 5 at 10:36 AMmarketbeat.com - July 5 at 10:29 AMmarketbeat.com - July 5 at 10:13 AMmarketbeat.com - July 5 at 10:10 AM Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ALLR Media Mentions By Week ALLR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLR News Sentiment▼-0.100.46▲Average Medical News Sentiment ALLR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLR Articles This Week▼31▲ALLR Articles Average Week Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aditxt News Bellerophon Therapeutics News Ampio Pharmaceuticals News Aptevo Therapeutics News China SXT Pharmaceuticals News Athersys News Evofem Biosciences News Evelo Biosciences News Neptune Wellness Solutions News SciSparc News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
